FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197140299> ?p ?o ?g. }

• W3197140299 endingPage "5310" @default.
• W3197140299 startingPage "5298" @default.
• W3197140299 abstract "The purpose of this meta-analysis was to summarize the published data regarding associations between occurrence of severe treatment related toxicity and low skeletal muscle mass (LSMM) in oncologic patients and to perform a meta-analysis based on a large sample.MEDLINE, Cochrane, and SCOPUS databases were screened for associations between LSMM and treatment related toxicity in oncologic patients up to June 2021. Overall, 48 studies met the inclusion criteria. The following data were extracted: authors, year of publication, study design, number of patients, influence of LSMM on treatment toxicity (odds ratios and confidence intervals). The methodological quality of the involved studies was checked according to the QUADAS instrument. The meta-analysis was undertaken by using RevMan 5.4 software. DerSimonian and Laird random-effects models with inverse-variance weights were used to account for the heterogeneity between the studies.The included 48 studies comprised 4803 patients with different malignant diseases. LSMM occurred in 1966 patients (40.9%). LSMM was associated with therapy toxicity (simple logistic regression) with an odds ratio OR = 2.19, CI95%= (1.78-2.68). LSMM was associated with DLT in patients underwent curative treatment (16 studies, 2381 patients) with OR = 2.48, CI95%= (1.77-3.48). LSMM predicted DLT in patients underwent palliative chemotherapy (30 studies, 2337 patients)with OR = 2.06, CI95%= (1.56-2.74). In the subgroups received different palliative therapies, relationships between LSMM and DLT were as follows: conventional chemotherapies (7 studies, 600 patients) OR = 2.14, CI95%= (1.38-3.31); different kinases inhibitors (13 studies, 906 patients) OR = 3.08, CI95%= (1.87-5.09); checkpoint inhibitors (7 studies, 557 patients) OR = 1.30, CI95%= (0.79-2.11).LSMM is an essential factor of treatment toxicity in oncologic patients. Association between LSMM and DLT is strongest in patients received therapy with kinases inhibitors. The influence of LSMM on DLT is lowest in patients underwent treatment with checkpoint inhibitors. The presence of LSMM should be included into radiological reports and provided to oncologists to optimize chemotherapy. LSMM should be included into dose calculation for chemotherapy." @default.
• W3197140299 created "2021-09-13" @default.
• W3197140299 creator A5033409292 @default.
• W3197140299 creator A5037386546 @default.
• W3197140299 creator A5037515221 @default.
• W3197140299 creator A5037553164 @default.
• W3197140299 creator A5046852939 @default.
• W3197140299 creator A5058914292 @default.
• W3197140299 creator A5060161983 @default.
• W3197140299 date "2021-10-01" @default.
• W3197140299 modified "2023-10-16" @default.
• W3197140299 title "Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis" @default.
• W3197140299 cites W1679349094 @default.
• W3197140299 cites W1912151765 @default.
• W3197140299 cites W1965907872 @default.
• W3197140299 cites W1973593314 @default.
• W3197140299 cites W2005850646 @default.
• W3197140299 cites W2006782694 @default.
• W3197140299 cites W2041554215 @default.
• W3197140299 cites W2046529949 @default.
• W3197140299 cites W2054865212 @default.
• W3197140299 cites W2061851543 @default.
• W3197140299 cites W2069539051 @default.
• W3197140299 cites W2101398993 @default.
• W3197140299 cites W2101997785 @default.
• W3197140299 cites W2107328434 @default.
• W3197140299 cites W2107638293 @default.
• W3197140299 cites W2121936556 @default.
• W3197140299 cites W2127206464 @default.
• W3197140299 cites W2140167330 @default.
• W3197140299 cites W2141402062 @default.
• W3197140299 cites W2152540368 @default.
• W3197140299 cites W2152963742 @default.
• W3197140299 cites W2157823046 @default.
• W3197140299 cites W2166926027 @default.
• W3197140299 cites W2169160087 @default.
• W3197140299 cites W2347023427 @default.
• W3197140299 cites W2505846117 @default.
• W3197140299 cites W2570443512 @default.
• W3197140299 cites W2596656713 @default.
• W3197140299 cites W2605180617 @default.
• W3197140299 cites W2622188477 @default.
• W3197140299 cites W2701848515 @default.
• W3197140299 cites W2738063223 @default.
• W3197140299 cites W2770357165 @default.
• W3197140299 cites W2774699776 @default.
• W3197140299 cites W2805520890 @default.
• W3197140299 cites W2807339691 @default.
• W3197140299 cites W2807467238 @default.
• W3197140299 cites W2808880030 @default.
• W3197140299 cites W2892626431 @default.
• W3197140299 cites W2895672555 @default.
• W3197140299 cites W2896047065 @default.
• W3197140299 cites W2897513125 @default.
• W3197140299 cites W2902884328 @default.
• W3197140299 cites W2911418323 @default.
• W3197140299 cites W2913291294 @default.
• W3197140299 cites W2921160785 @default.
• W3197140299 cites W2921796589 @default.
• W3197140299 cites W2931796906 @default.
• W3197140299 cites W2944160416 @default.
• W3197140299 cites W2945877501 @default.
• W3197140299 cites W2957186036 @default.
• W3197140299 cites W2970328232 @default.
• W3197140299 cites W2973231291 @default.
• W3197140299 cites W2979468785 @default.
• W3197140299 cites W2988614685 @default.
• W3197140299 cites W2991687469 @default.
• W3197140299 cites W2993493576 @default.
• W3197140299 cites W2994037520 @default.
• W3197140299 cites W2997698510 @default.
• W3197140299 cites W2999923851 @default.
• W3197140299 cites W3004873719 @default.
• W3197140299 cites W3005030826 @default.
• W3197140299 cites W3012963307 @default.
• W3197140299 cites W3018028859 @default.
• W3197140299 cites W3025026082 @default.
• W3197140299 cites W3027391335 @default.
• W3197140299 cites W3029930846 @default.
• W3197140299 cites W3033563124 @default.
• W3197140299 cites W3045806419 @default.
• W3197140299 cites W3046984254 @default.
• W3197140299 cites W3047551019 @default.
• W3197140299 cites W3048700260 @default.
• W3197140299 cites W3078459668 @default.
• W3197140299 cites W3083337362 @default.
• W3197140299 cites W3108006468 @default.
• W3197140299 cites W3121925193 @default.
• W3197140299 cites W3123356709 @default.
• W3197140299 cites W3199784844 @default.
• W3197140299 cites W353895993 @default.
• W3197140299 cites W4248192898 @default.
• W3197140299 cites W4294215472 @default.
• W3197140299 doi "https://doi.org/10.1016/j.clnu.2021.08.023" @default.
• W3197140299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34536638" @default.
• W3197140299 hasPublicationYear "2021" @default.
• W3197140299 type Work @default.
• W3197140299 sameAs 3197140299 @default.

• next